yep which is in line with my expectation that they will need to...

yep which is in line with my expectation that they will need to raise capital around mid 2022, which will have the benefit of the phase 1 update end of this year which will give investors a first look at clinical data using CLTX. They may even squeeze in another patient update as well, with cohort 3 being a meaningful dose... and one that we can expect to see some meaningful clinical benefit.

They may well have another asset on board by then, as well as being ready to commence the phase 1 trial on CDH-17, and CLTX basket trial .. which will be ample justification for a capital raise i.e. to develop the pipeline.